Long Zone Holdings Inc. Buys 10,000 Shares of Knight Therapeutics Inc (GUD) Stock

Share on StockTwits

Knight Therapeutics Inc (TSE:GUD) insider Long Zone Holdings Inc. acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average price of C$7.39 per share, for a total transaction of C$73,900.00. Following the completion of the transaction, the insider now owns 21,621,433 shares in the company, valued at C$159,782,389.87.

TSE:GUD opened at C$7.41 on Friday. Knight Therapeutics Inc has a 1-year low of C$7.10 and a 1-year high of C$8.81. The company has a debt-to-equity ratio of 0.10, a quick ratio of 32.24 and a current ratio of 32.29. The firm has a market capitalization of $1.06 billion and a P/E ratio of 47.20.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, May 9th. The company reported C$0.04 earnings per share for the quarter, beating analysts’ consensus estimates of C$0.03 by C$0.01. The firm had revenue of C$2.96 million during the quarter, compared to analysts’ expectations of C$3.06 million. Analysts forecast that Knight Therapeutics Inc will post 0.170000009558233 earnings per share for the current fiscal year.

Separately, Raymond James set a C$10.25 price objective on shares of Knight Therapeutics and gave the company an “outperform” rating in a research report on Friday, March 15th.

TRADEMARK VIOLATION NOTICE: “Long Zone Holdings Inc. Buys 10,000 Shares of Knight Therapeutics Inc (GUD) Stock” was first posted by Macon Daily and is the property of of Macon Daily. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://macondaily.com/2019/05/24/long-zone-holdings-inc-buys-10000-shares-of-knight-therapeutics-inc-gud-stock.html.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Recommended Story: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.